ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2291

Optimal Hydroxychloroquine Drug Levels in Pregnant Women with Systemic Lupus Erythematosus

Stephen Balevic1, Michael Cohen-wolkowiez 2, Amanda Eudy 3, Mara Becker 4, Laura Schanberg 5 and Megan Clowse 3, 1Duke University, Hillsborough, NC, 2Duke University, Durham, NC, 3Duke University, Durham, 4Duke Children's Hospital, Durham, NC, 5Duke University Medical Center, Durham, NC

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Hydroxychloroquine, Lupus and pregnancy

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: Reproductive Issues In Rheumatic Disorders Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Pregnancies in women with systemic lupus erythematosus (SLE) often result in preterm birth. Active disease during pregnancy significantly increases the risks for these poor outcomes. Hydroxychloroquine (HCQ) reduces disease activity and flares in SLE, however, low serum levels may lead to treatment failure. Therefore, our objective is to evaluate HCQ levels during pregnancy and determine target serum levels to reduce maternal disease activity and preterm birth.

Methods: We performed a single-center observational study of women with SLE who were taking HCQ during pregnancy between 2013 and 2019. Serum samples were analyzed using validated high-performance liquid chromatography/mass spectrometry. Based on prior publications, we analyzed average HCQ exposure both continuously and categorically: ≤ 100 ng/ml (low), 101-500 ng/mL (moderate), and > 500 ng/ml (high). The primary maternal outcome was disease activity, measured using the Physician Global Assessment (PGA) throughout pregnancy. The primary neonatal outcome was gestational age at birth. We excluded pregnancies in which the woman had lupus nephritis within the prior 3 years due to potential confounding between drug levels and preterm birth. We analyzed categorical outcomes using Fisher’s exact test and continuous outcomes using linear regression models, Wilcoxon signed-rank test, Kruskal-Wallis test, t test, and ANOVA.

Results: We analyzed 172 samples from 52 pregnancies in 46 women (Table 1). HCQ concentration varied widely among individuals at each trimester. In addition, there was a non-statistically significant decline in HCQ concentrations throughout pregnancy, with a nadir in the 3rd trimester. Of live births (n=38), preterm birth was significantly more common in mothers whose average HCQ level was low (62.5%), compared to those with moderate levels (8.3%), and high levels (33.3%, p=0.005), Table 2. In addition, disease activity in these mothers was significantly higher in those with low HCQ levels (median [IQR]) PGA 0.67 [0.36-1.16], compared to those with moderate levels (0.06 [0-0.37]), and high levels (0.38 [0.25-0.5], p=0.006). The association between PGA and HCQ levels as a continuous variable was best characterized using a generalized linear model with a log function (figure 1, p=0.002).

Conclusion: Our data suggests that the optimal serum HCQ level in this cohort appears to be in the moderate range (101-500 ng/ml), with this group having the lowest maternal disease activity and the fewest preterm births. Women with the lowest HCQ levels, in the range concerning for medication non-adherence, had the highest lupus activity and rates of preterm birth. However, the relationship between HCQ drug levels and neonatal outcomes are complex and not linear, and some women with high exposure (levels >500 ng/mL) continue to experience SLE activity and preterm birth. Due to low sample sizes within subgroups, ongoing data collection and analyses will clarify the role of monitoring HCQ levels in lupus pregnancies, characterize the relationship between drug levels and medication adherence, and determine the need for HCQ dose adjustment through PK/PD modeling.


ACR abstract_Table 1

Table 1. Demographics -excluding lupus nephritis-


ACR abstract_Table 2

Table 2: Maternal and Neonatal Outcomes by Categorical HCQ Exposure -excluding lupus nephritis-


ACR abstract_Figure 1

Figure 1: Lupus Disease Activity vs HCQ Level -all pregnancies, excluding lupus nephritis-*


Disclosure: S. Balevic, UCB, 5, Rheumatology Research Foundation, 2, Thrasher Research Foundation, 2, NIH, 2; M. Cohen-wolkowiez, Cempra, 5, Cidara Therapeutics, 5, UCB, 5, Jacobus, 5, Biomedical Advanced Research and Development Authority, 2, NIH, 2, FDA, 2; A. Eudy, GSK, 2; M. Becker, NIH/NCATS, 2, FDA, 9, CARRA, 9, ACR, 6; L. Schanberg, CARRA, 9, Childhood Arthritis and Rheumatology Research Alliance, 2, Sanofi, 5, 9, SOBI, 5, UCB, 5; M. Clowse, GSK, 2, UCB, 5.

To cite this abstract in AMA style:

Balevic S, Cohen-wolkowiez M, Eudy A, Becker M, Schanberg L, Clowse M. Optimal Hydroxychloroquine Drug Levels in Pregnant Women with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/optimal-hydroxychloroquine-drug-levels-in-pregnant-women-with-systemic-lupus-erythematosus/. Accessed April 11, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/optimal-hydroxychloroquine-drug-levels-in-pregnant-women-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.